ISM9077 (Target Y inhibitor)
Insilico Medicine: company profile
Preclinical candidate per company
Since , the date of the source that reports this phase.
Summary
ISM9077 is a Target Y inhibitor from Insilico Medicine. The source describes it as small molecule. It is being developed for ocular, inflammatory and aging-related diseases. Per the company, it was at Preclinical candidate as of Aug 14, 2026. The AI role named in the source is target and molecule design. About the company: Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation. The latest dated source is from Aug 14, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Insilico Medicine
- Indication
- Ocular, inflammatory and aging-related diseases
- Therapeutic area
- Ophthalmology, Immunology and inflammation, Aging
- Modality
- Small molecule
- AI role
- Target and molecule design
- Phase in the source
- Preclinical candidate, as of Aug 14, 2026
- Phase source
- X only
- Board column
- Preclinical
- Trial record
- none (preclinical)
AI evidence
AI source: Company
“ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models”
Milestone timeline
-
Official X post: Preclinical candidate
About Insilico Medicine
Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation.
Spot an error? Tell me and I'll fix it.